Core Insights - The report emphasizes the significant role of phosphoramidite monomers in the small nucleic acid industry chain, highlighting their impact on the development of small nucleic acid drugs, which are considered promising candidates for treating various diseases due to their unique molecular structures and therapeutic mechanisms [1][6][10] - The report predicts robust growth in the demand for phosphoramidite monomers, with multinational pharmaceutical companies likely to benefit from this trend, as the global nucleotide market is projected to reach USD 730 million in 2023, with China being the largest production market [10][11] Section Summaries Phosphoramidite Monomer's Role - Phosphoramidite monomers are crucial raw materials for synthesizing small nucleic acid drugs, enhancing their stability and biological activity, and driving innovation in drug development [6][9] - The solid-phase phosphoramidite method is the mainstream technique for synthesizing oligonucleotides, which are a major cost component in nucleic acid drug production [9] Market Dynamics - The report notes that 90% of global nucleotides are used for nucleic acid drug production, with only about 10% allocated to health foods and agriculture [10] - The small nucleic acid drug market is primarily dependent on major multinational pharmaceutical companies, indicating potential benefits for companies within their supply chains [11] Investment Recommendations - The report suggests focusing on innovative drug companies such as Furuya Co., OncoOne, and others, as well as raw material suppliers like WuXi AppTec and others, indicating a diverse range of investment opportunities in the sector [10]

Macro and Strategy Research - The report emphasizes the need for "high-quality" development, with a focus on technology and reform as the main themes for the upcoming five years [2][3] - The "15th Five-Year Plan" will specifically highlight "technological self-reliance" and "comprehensive deepening of reform," indicating a shift towards more concrete and detailed goals compared to the previous plan [2][3] - The modern industrial system will prioritize "intelligent, green, and integrated" development, with advanced manufacturing playing a crucial role [3] - The report stresses the importance of domestic circulation and consumer demand, aiming to enhance living standards and stimulate new consumption [4] - There is a strong emphasis on social welfare, including education and social security, to address the immediate concerns of the populace [5] - The report outlines a commitment to accelerate the green transition and build a new energy system, with specific targets for carbon neutrality and renewable energy [6] Fixed Income Research - The report notes a narrow fluctuation in interest rates, with the yield curve flattening, indicating a stable but cautious market environment [12][14] - Recent fiscal data shows an improvement in tax revenue due to inflation, while government spending is increasingly focused on technology and public welfare [12] - The issuance of local government bonds has been significant, with a total of 789.5 billion yuan issued, aimed at stabilizing economic operations in the fourth quarter [13] - The bond market is currently influenced by uncertainties in U.S.-China relations and expectations of monetary policy adjustments [14] Industry Research - The report highlights significant achievements by Chinese pharmaceutical companies at the ESMO conference, showcasing advancements in cancer treatment and innovative therapies [18][19] - A notable collaboration between Innovent Biologics and Takeda Pharmaceuticals has been established, with a potential total deal value of up to 11.4 billion USD, marking a significant milestone in the Chinese biopharmaceutical sector [19][20] - The report indicates a mixed performance in the pharmaceutical sector, with a slight decline in the industry index, but suggests that the outlook remains positive due to ongoing innovation and market opportunities [19][20]

Core Viewpoint - Roche's drug, Ocrelizumab (brand name: Gazyva/Gazyvaro), has received FDA approval for a new indication to treat adult patients with active lupus nephritis (LN) who are undergoing standard treatment [1] Group 1: Drug Approval and Indication - Ocrelizumab is the first CD20-targeted therapy approved by the FDA for the treatment of lupus nephritis [1] - The approval is based on positive results from the Phase II NOBILITY study and the Phase III REGENCY study [1] Group 2: Clinical Study Results - In the REGENCY study, 46.4% of patients receiving Ocrelizumab combined with standard treatment achieved complete renal response (CRR) at week 76, compared to 33.1% in the standard treatment group (adjusted difference of 13.4%, 95% CI: 2.0%-24.8%; P=0.0232) [1] - The Ocrelizumab group also showed clinically meaningful improvements in complement levels, as well as reductions in anti-dsDNA antibodies, disease activity, and inflammatory markers compared to the standard treatment group [1]